Thomas Axelsson winner of the Arthur D. Little Nordic Life Science Award 2016
Vitrolife’s CEO, Thomas Axelsson, has been named as the winner of the Arthur D. Little Nordic Life Science Award for 2016. The prize will be awarded at a ceremony in Stockholm on January 26, 2017.
– I am very pleased and honored to have been chosen as the winner of this prize. It is a prize that has been awarded to many successful people in Life Science over the years, says Thomas Axelsson.
Since Thomas Axelsson took up his position in 2011, Vitrolife has broadened its product portfolio both through its own product development and through acquisitions. The Vitrolife Group has international medical device operations and a strong position within the field of assisted reproduction. The company was founded in 1994 and has been listed on NASDAQ Stockholm since 2001. Sales amount to approximately SEK 800 million and profits have grown strongly in recent years.
– The Arthur D. Little Nordic Life Science Award is a leadership prize that has been awarded annually since 2002. The prize was instituted as Life Science needs models to enable the field and the companies in the field to grow. Skilful leaders who build up new companies are needed to this end, says Nils Bohlin, the initiator of the prize with global responsibility for Arthur D. Little’s Healthcare & Life Sciences field of operations.
– Under Thomas’ leadership, Vitrolife has built a leading global position within the field of in vitro fertilization and created great sustainable shareholder value through continued focus on quality and the development of new technologies, says Ulrica Sehlstedt, who is responsible for Healthcare & Life Sciences at Arthur D. Little, Nordic Region.
The prize is awarded to a person in the Nordic region who has displayed very good leadership qualities in the field of Life Science. The business should be based on strong entrepreneurial skills and a high level of scientific knowledge.
Gothenburg, January 12, 2017
VITROLIFE AB (publ)
Thomas Axelsson, CEO
For further information, please contact:
Thomas Axelsson, CEO, 46 31 721 80 01
Dr. Ulrica Sehlstedt, Partner, Arthur D. Little, phone +46 708 83 00 39
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
_________________________________________________________________________________________________________________
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.Vitrolife has approximately 330 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, China, Denmark, France, Germany, Hungary, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.
_________________________________________________________________________________________________________________
Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. Arthur D. Little is present in more than 35 locations around the world and has been established in the Nordics since 1993, currently with offices in Stockholm, Oslo and Gothenburg.
_________________________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
Tags: